ABSTRACT
Epilepsy is a condition resulting from complex interactions involving excessive neuronal electrical activity and oxidative stress, which can lead to chronic neurological conditions. This study evaluates crocin encapsulated in SLNC for neuroprotective and countering pentylenetetrazole (PTZ) -induced oxidative damage. The rats were pre-treated with SLNC and FC (25, 50 mg/kg/day; P.O.) for 28 days before being induced with PTZ. Various standard tests were conducted to assess their behavioral functions, such as Y-maze, Open field test (OFT), and elevated plus maze (EPM) tests. ELISA measured brain tissue catalase activity (CAT) and nitric oxide status (NO). The expression of Nuclear factor kappa B (NF-κB) and the number of dendrite spines were examined through Immunohistochemical and Golgi-Cox staining, respectively. The Pretreating rats with SLNC plus PTZ significantly boosted memory and reduced anxiety levels in Y-maze, OFT, and EPM tests. In addition, it decreased NO levels and increased CAT levels. SLNC also showed a significant decrease in NF-κB expression and an increase in neurons and the number of spines. The positive effects of SLNC in improving memory and learning deficits after PTZ injection can be attributed to its anti-inflammatory and anti-oxidative effects.
ABSTRACT
Alzheimer's disease (AD) is one of the chief neurological difficulties in the aged population, identified through dementia, memory disturbance, and reduced cognitive abilities. ß-amyloid (Aß) plaques aggregations, generation of reactive oxygen species, and mitochondrial dysfunction are among the major signs of AD. Regarding the urgent need for the development of novel treatments for neurodegenerative diseases, researchers have recently perused the function of natural phytobioactive combinations, such as resveratrol (RES), in vivo and in vitro (animal models of AD). Investigations have shown the neuroprotective action of RES. This compound can be encapsulated by several methods (e.g. polymeric nanoparticles (NPs), solid lipid nanoparticles, Micelles, and liposomes). This antioxidant compound, however, barely crosses the blood-brain barrier (BBB), thereby limiting its bioavailability and stability at the target sites in the brain. Thanks to nanotechnology, the efficiency of AD therapy can be improved by encapsulating the drugs in a NP with a controlled size (1-100 nm). This article addressed the use of RES, as a Phytobioactive compound, to decrease the oxidative stress. Encapsulation of this compound in the form of nanocarriers to treat neurological diseases to improve BBB crossing is also discussed.
Subject(s)
Alzheimer Disease , Nanoparticles , Animals , Alzheimer Disease/drug therapy , Resveratrol/therapeutic use , Brain/metabolism , Amyloid beta-Peptides , Blood-Brain Barrier/metabolismABSTRACT
Neuroleptic drugs such as haloperidol has side effects on extrapyramidal pathways. Tardive Dyskinesia is the most important complication. The most characteristic feature of this Tardive Dyskinesia is involuntary movements of mouth and face. In regard to this problem, the induction of gliosis and cell death in the nervous tissue are considered. In this study, adult Sprague-Dawley rats were used as experimental models. Rats were divided into control and experimental groups. The rats were kept in the animal house under standard conditions during experiments. The control rats were intraperitoneally treated with normal saline for 6 days. The experimental samples were treated for the same time with 2, 5 and 10 mg haloperidol. After the trial period, the rats were killed following general anesthesia and their brains were removed after perfusion with a 4 percent formalin solution. Then, 1 mm cuts of the brains were obtained. After that, 5 um tissue sections were prepared and stained with hematoxylin and eosin. The stained sections were examined by optical microscopy. The results showed that the short-term use of haloperidol does not lead to gliosis process in the rat cerebral cortex. The short-term use of 10 mg haloperidol results in cell death in the rat cerebral cortex. Cell death was not observed in the control group and the groups that had received 2 mg and 5 mg doses of haloperidol. According to previous studies, it can be concluded that the gliosis process is induced in the cerebral cortex only following the long-term use of haloperidol. It is considered as a secondary cause of the neuroleptic drugs side effects. The primary cause of these side effects is the induction of cell death in neurons.
Los fármacos neurolépticos como el haloperidol tiene efectos secundarios sobre las vías extrapiramidales. La discinesia tardía es la complicación más importante. El rasgo más característico de esta discinesia tardía son movimientos involuntarios de la boca y cara. En lo que respecta a este problema, se consideran la inducción de gliosis y muerte celular en el tejido nervioso. En este estudio, fueron utilizados ratas Sprague - Dawley adultas como modelos experimentales. Las ratas se dividieron en grupos control y experimentales, y se mantuvieron en condiciones estándar durante los experimentos. Las ratas control fueron tratadas por vía intraperitoneal con solución salina normal durante 6 días, y las experimentales durante el mismo tiempo con 2 , 5 y 10 mg de haloperidol. Luego, las ratas se sacrificaron y sus cerebros se extrajeron después de la perfusión con una solución de formalina al 4 por ciento, obteniendo cortes de 1 mm de los cerebros. Se prepararon y se tiñeron con hematoxilina y eosina en secciones de tejido de 5 micras, y se examinaron por microscopía óptica. Se observó que el uso a corto plazo del haloperidol no conduce a proceso de gliosis en la corteza cerebral de rata. El uso a corto plazo de 10 mg de haloperidol produjo muerte celular en la corteza cerebral de rata. La muerte celular no se observó en el grupo control ni en los grupos que habían recibido 2 y 5 mg de haloperidol. De acuerdo con estudios anteriores, se concluye que el proceso de gliosis se induce en la corteza cerebral sólo tras el uso a largo plazo de exposición al haloperidol. Se considera como una causa secundaria de los efectos adversos de los fármacos neurolépticos. La principal causa de estos efectos secundarios, es la inducción de muerte celular en neuronas.